Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.2352W HIGH $8.14
Volume
74.94 K
Value Traded
115.31 K
Short % Float
2.43%
-1.57%Week
-11.35%1 Month
-16.67%3 Month
-52.11%6 Month
-98.34%5 Year
-98.34%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
6.95 M
EPS (TTM)
-1.75
P/E Ratio
-
Ent. Value
-3.71 M
Total Shares
5.56 M
Float Shares
5.11 M
Insiders
8.12%
Institutions
2.15%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ACXP Catalyst Timeline
Dated clinical, regulatory and corporate events for Acurx Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Acurx Pharmaceuticals, Inc.
322Total events
15Upcoming
37Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲First Patient DosedIbezapolstatFiledTrial
First patient enrolled in PATHFINDER Phase 2 trial of ibezapolstat in multiply-recurrent CDI
multiply-recurrent C. difficile Infection (rCDI)source ↗
●Trial InitiationIbezapolstatFiledTrial
PATHFINDER Phase 2 trial of ibezapolstat currently enrolling
multiply-recurrent C. difficile Infection (rCDI)source ↗
▲Trial InitiationIbezapolstatFiledTrial
IBZ-PATHFINDER trial start-up activities initiated
multiply-recurrent CDI (rCDI)source ↗
▲FDA Feedback ReceivedIbezapolstatFiledFDA Meeting
FDA conditional acceptance of brand name CIFBEZY
●Trial CompletionIbezapolstatFiledTrial
Phase 2 clinical trial completed
Clostridioides difficile Infection (CDI)source ↗
▲FDA Filing AcceptedIbezapolstatFiledRegulatory Filing
FDA conditional acceptance of brand name CIFBEZY
▲Trial InitiationIbezapolstatFiledTrial
Trial start-up activities initiated for IBZ-PATHFINDER Phase 2 trial in rCDI
multiply-recurrent CDI (rCDI)source ↗
▲Patent GrantedIbezapolstatFiledIP / Competition
Mexico Patent Office granted new patent covering DNA Polymerase IIIC inhibitors including ibezapolstat
▲Partnership / LicenseCorporate
New scientific partnership with Leiden University Medical Center
▲Trial InitiationIbezapolstatFiledTrial
Trial start-up activities initiated for IBZ-PATHFINDER Phase 2 trial
recurrent Clostridioides difficile Infectionsource ↗
▲Preclinical PoCPreclinical
Initial data from MRSA-infected neutropenic mice reported
MRSA infectionssource ↗
▲FDA Feedback ReceivedIbezapolstatFiledFDA Meeting
FDA guidance received in meeting minutes from Type C Meeting
Clostridioides difficile infectionsource ↗
▲Trial InitiationIbezapolstatFiledTrial
IBZ-PATHFINDER trial start-up activities initiated
recurrent Clostridioides difficile infectionsource ↗
▲Other Regulator MilestoneIbezapolstatFiledEx-US Regulatory
Received FDA Conditional Acceptance and USPTO Trademark Allowance for proprietary name
C. difficile Infectionsource ↗
▲Patent GrantedIbezapolstatFiledIP / Competition
Japan and Mexico Patent Offices granted new patents for DNA pol IIIC inhibitors
▲FDA Feedback ReceivedIbezapolstatFiledFDA Meeting
FDA Conditional Acceptance of proprietary name for ibezapolstat
C. difficile Infectionsource ↗
●Type C MeetingIbezapolstatFiledFDA Meeting
Type C Meeting with FDA on ibezapolstat Phase 3 program and planned NDA scope
C. difficile Infection (CDI)source ↗
▲FDA Feedback ReceivedIbezapolstatFiledFDA Meeting
FDA Type C Meeting feedback on Phase 3 program
Clostridioides difficile Infection (CDI)source ↗
▲Trial InitiationIbezapolstatFiledTrial
Start-up activities initiated for rCDI pilot trial
multiply-recurrent C. difficile infection (rCDI)source ↗
▲FDA Feedback ReceivedIbezapolstatFiledFDA Meeting
Final EMA and FDA agreement for ibezapolstat pivotal Phase 3 trials
C. difficile infection (CDI)source ↗
▲Poster PresentationIbezapolstatFiledPresentation
Poster presentation on microbiome preservation data of ibezapolstat at Anaerobe Society of the Americas Congress
Multiply-recurrent Clostridioides difficile Infection (rCDI)source ↗
●Type B MeetingIbezapolstatFiledFDA Meeting
FDA meeting to discuss single phase 3 study as pivotal trial
C. difficile Infectionsource ↗
●Oral PresentationIbezapolstatFiledPresentation
Data presented at Anaerobe Society of the Americas Congress
C. difficile Infectionsource ↗
▲Partnership / LicenseCorporate
Continued scientific partnership with Leiden University Medical Center
▲Oral PresentationIbezapolstatFiledPresentation
Presentation of cryo-EM structure of ibezapolstat bound to DNA pol IIIC at LED3 conference
Gram-positive bacterial infectionssource ↗
▲Partnership / LicenseCorporate
Research grant from Dutch government to Leiden University Medical Center and Acurx for DNA pol IIIC inhibitors
Gram-positive infectionssource ↗
▲Poster PresentationPresentation
Poster presentation of preclinical microbiome evaluation of DNA pol IIIC inhibitors at ESCMID Global 2026
Gram-positive infectionssource ↗
▼Equity OfferingCorporate
Closing of registered direct offering raising $2.5 million upfront with potential additional $4.6 million from warrant exercise
●Poster PresentationIbezapolstatFiledPresentation
Poster presented at ESCMID Global 2026 showing gut microbiome preservation and systemic antibacterial activity of oral DNA pol IIIC inhibitors
Gram-positive bacterial infectionssource ↗
▲Patent GrantedACX-375CIP / Competition
Korean Patent Office grants patent for DNA Polymerase IIIC inhibitors covering ACX-375C program
▲Trial InitiationIbezapolstatFiledTrial
Launch of open-label pilot trial in multiply-recurrent CDI
multiply-recurrent C. difficile Infection (rCDI)source ↗
◆Trial InitiationIbezapolstatFiledTrial
Initiation of open-label pilot trial in patients with multiply-recurrent CDI
recurrent C. difficile infection (rCDI)source ↗
▲Patent GrantedIbezapolstatFiledIP / Competition
Korean Patent Office granted new patent for DNA pol IIIC inhibitors
C. difficile infectionsource ↗
▲Trial InitiationIbezapolstatFiledTrial
Started open-label pilot Phase 2 trial of ibezapolstat in patients with multiply-recurrent CDI
recurrent C. difficile infection (rCDI)source ↗
▲Patent GrantedIP / Competition
USPTO grants new patent US 12,534,470 covering DNA Polymerase IIIC inhibitors including compositions-of-matter, methods of use, and pharmaceutical compositions
▲Patent GrantedIbezapolstatFiledIP / Competition
USPTO granted new patent for DNA pol IIIC inhibitors covering composition of matter and method of use, extending to December 2039
C. difficile infectionsource ↗
▲FDA Feedback ReceivedIbezapolstatFiledFDA Meeting
Mutually consistent positive feedback from FDA and EMA on Phase 3 trial design
Acute CDIsource ↗
▲EU MAA SubmissionIbezapolstatFiledEx-US Regulatory
EMA Scientific Advice Procedure completed; agreement on Phase 3 program supports future MAA submission
C. difficile Infection (CDI)source ↗
▲PublicationIbezapolstatFiledPresentation
Nature Communications publication on PolC inhibitor structures including ibezapolstat and ACX-801
▲EU MAA SubmissionIbezapolstatFiledEx-US Regulatory
EMA positive regulatory guidance for ibezapolstat Phase 3 program and MAA submission
Clostridioides difficile infectionsource ↗
◆Trial InitiationIbezapolstatFiledTrial
Ibezapolstat international Phase 3 registration program to commence
Clostridioides difficile infectionsource ↗
◆Quarterly UpdateCorporate
Third Quarter 2025 Financial Results Conference Call and Business Update
▼Equity OfferingCorporate
Raised additional $1.4 million from warrant exercise by institutional investor
▲EU MAA SubmissionIbezapolstatFiledEx-US Regulatory
Received positive regulatory guidance from EMA supporting Phase 3 program and future MAA submission
C. difficile Infectionsource ↗
Past FDA Catalysts and PDUFA Decisions
How ACXP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D29 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 70%
Micro Cap(rank 461 of 658)
Percentile Rank
Acurx Pharmaceuticals, Inc. faces pipeline headwinds (29/100), with $60M risk-adjusted pipeline value, led by Ibezapolstat in Clostridium Difficile Infection (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ibezapolstat Small moleculeCompletedNCT04247542 | Clostridium Difficile Infection | Phase 2 | COMPLETED | 53 | Nov 15, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every ACXP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ibezapolstat Fast TrackRMATOrphan | C. difficile infection | Phase 3 | 2026-06-16 | High-resolution cryo-electron microscopy resolved the structure of ibezapolstat in relationship to the binding pocket of a Gram-positive DNA pol IIIC to the level of 3.2Å; The active site of the polymerase is conserved in >220 Gram-positive speciesRead More | Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific ConferenceRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sailer CarlDirector | Grant/Award | 2,150 2,150 held | $0.00 | 04/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ACXP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ACXP for Q2 2026. | ||||
ACXP Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ACXP ranks across every disease it competes in
Competitive Position is a premium feature
See how ACXP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialACXP News
ACXPAcurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
Acurx Pharmaceuticals has enrolled the first patient in its PATHFINDER Phase 2 clinical trial for ibezapolstat, targeting multiply-recurrent C. difficile infection (rCDI). This trial aims to support a future NDA submission based on a single Phase 3 trial. The company is also preparing for the ASPIRE Phase 3 trial, pending funding, to further assess ibezapolstat's efficacy against standard treatments.
Read more →ACXPAcurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures
Acurx Pharmaceuticals presented a scientific poster at the International C. difficile Symposium, showcasing the superior in vitro kill kinetics of ibezapolstat compared to vancomycin and fidaxomicin against C. difficile and vancomycin-resistant Enterococcus. The findings indicate that ibezapolstat maintains effective bactericidal activity even in complex co-culture environments, potentially addressing significant unmet needs in CDI treatment. The company is advancing its clinical trials, including a Phase 3 program.
Read more →ACXP▲ +18.3%on this news
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat
Acurx Pharmaceuticals has received FDA conditional acceptance for the brand name CIFBEZY for its lead antibiotic candidate, ibezapolstat, which targets C. difficile infections. The USPTO has also granted a trademark allowance for the name. These milestones are crucial as the company prepares for international Phase 3 clinical trials aimed at treating and preventing recurrence of CDI.
Read more →ACXP▼ -5.7%on this newsshared move
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
Acurx Pharmaceuticals reported its Q2 2026 results, highlighting successful funding efforts and advancements in its antibiotic candidate ibezapolstat. The company secured new patents and received FDA guidance for a Phase 3 trial. Despite a net loss of $2.3 million, the company is optimistic about its future, particularly regarding its innovative antibiotic development.
Read more →ACXPJapan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics
Acurx Pharmaceuticals has received new patents from Japan and Mexico for its DNA Polymerase IIIC inhibitors, enhancing its intellectual property portfolio. The company is preparing for Phase 3 clinical trials of its lead product candidate, ibezapolstat, targeting Clostridioides difficile Infection. FDA guidance suggests a potential NDA submission based on a single Phase 3 trial, contingent on successful outcomes.
Read more →ACXPAcurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics
Acurx Pharmaceuticals has announced a scientific partnership with Leiden University Medical Center to develop DNA polymerase IIIC inhibitor antibiotics. This collaboration aims to generate the first 3D structure of PolC from MRSA, enhancing the discovery of new antibiotics for resistant infections. The partnership builds on prior successful research funded by Health-Holland.
Read more →ACXPFDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection
Acurx Pharmaceuticals received positive guidance from the FDA regarding its ibezapolstat Phase 3 clinical program. The FDA indicated that a single Phase 3 trial could suffice for a New Drug Application (NDA) submission, contingent on robust clinical data. The IBZ-ASPIRE trial is set to evaluate ibezapolstat's efficacy against standard care in treating Clostridioides difficile infection. Acurx is also initiating a pilot trial, IBZ-PATHFINDER, for recurrent CDI.
Read more →ACXPAcurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection
Acurx Pharmaceuticals presented data on ibezapolstat's ability to preserve beneficial gut bacteria in patients with multiply-recurrent Clostridioides difficile infection (rCDI). The data suggests that ibezapolstat may allow for microbiome repopulation, potentially preventing recurrence. The company is initiating a clinical trial for rCDI, with the first patient expected to enroll soon.
Read more →ACXP▼ -6.2%on this news
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update
Acurx Pharmaceuticals will discuss its second quarter 2026 financial results on August 14, 2026. The call will be hosted by CEO David P. Luci and CFO Robert G. Shawah. The company is advancing its lead antibiotic candidate, ibezapolstat, into international Phase 3 trials for treating C. difficile infections, following FDA designations that support its development.
Read more →ACXPAcurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference
Acurx Pharmaceuticals announced positive results from its collaboration with Leiden University Medical Center regarding its DNA pol IIIC inhibitors. The findings, presented at the LED3 Scientific Conference, highlight the potential of ibezapolstat as a targeted treatment for Gram-positive bacterial infections. The company is preparing to advance ibezapolstat into international Phase 3 clinical trials for C. difficile infection.
Read more →ACXP▼ -6%on this news
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
Acurx Pharmaceuticals reported its Q1 2026 results, highlighting a new patent for DNA pol IIIC inhibitors and the initiation of a clinical trial for recurrent CDI. The company achieved a 96% clinical cure rate in previous trials and is preparing for a Phase 3 trial pending favorable outcomes. Despite a net loss of $1.7 million, Acurx has secured funding for its clinical programs.
Read more →ACXPAcurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
Acurx Pharmaceuticals announced the presentation of a scientific poster at the ESCMID Global 2026, showcasing the microbiome evaluation of its DNA pol IIIC inhibitors. The findings suggest these compounds effectively target resistant Gram-positive infections while preserving gut microbiome integrity. This could lead to significant advancements in antibiotic therapy, minimizing complications associated with traditional antibiotics.
Read more →ACXPAcurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
Acurx Pharmaceuticals will present at the A.G.P. Healthcare Company Showcase on May 24, 2025. CEO David P. Luci will participate in a virtual fireside chat. The company is focused on developing a new class of antibiotics, with its lead candidate ibezapolstat ready for Phase 3 trials targeting recurrent C. difficile infections.
Read more →ACXPAcurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
Acurx Pharmaceuticals announced a conference call on May 12, 2026, to discuss its Q1 financial results and provide a business update. The company is advancing its lead antibiotic candidate, ibezapolstat, into international Phase 3 trials for treating C. difficile infections. Acurx has secured regulatory agreements for its trial designs from both the EMA and FDA.
Read more →ACXPAcurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals, Inc. has announced the closing of a registered direct offering, raising $2.5 million upfront, with potential additional proceeds of $4.6 million from short-term warrants. The funds will support working capital and corporate purposes. Acurx's lead antibiotic candidate, ibezapolstat, is set to advance to Phase 3 trials for treating C. difficile infections.
Read more →ACXP▼ -19.7%on this newsshared move
Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals announced a registered direct offering of up to $7.1 million, which includes $2.5 million upfront and potential additional proceeds from short-term warrants. The funds will be used for working capital and advancing their antibiotic candidate, ibezapolstat, into clinical trials. The offering is subject to customary closing conditions and is expected to close on April 16, 2026.
Read more →ACXP▼ -6.9%on this news
Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
Acurx Pharmaceuticals has received a new patent from the Korean Intellectual Property Office for its DNA Polymerase IIIC inhibitors. This patent enhances Acurx's intellectual property portfolio, which includes multiple patents in various countries. The company is preparing to advance its lead compound, ibezapolstat, to Phase 3 trials for treating acute C. difficile infection.
Read more →ACXP▼ -22.6%on this news
Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update
Acurx Pharmaceuticals reported its financial results for the fourth quarter and full year ended December 31, 2025, highlighting a significant improvement in cash position and reduced expenses. The company is preparing for international Phase 3 clinical trials for its lead antibiotic candidate, ibezapolstat, which has received positive feedback from the EMA. However, Acurx continues to face net losses and must secure financing to advance its clinical programs.
Read more →ACXP▲ +44.8%on this news· ran to +271% by day 3
Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection
Acurx Pharmaceuticals has announced a new clinical trial program for ibezapolstat, targeting recurrent Clostridioides difficile infection (rCDI). The program includes an open-label pilot trial followed by a Phase 3 registration trial, pending funding. The company aims to demonstrate ibezapolstat's effectiveness in both treating and preventing rCDI, potentially shifting treatment paradigms. Positive Phase 2 results support their confidence in advancing the drug.
Read more →About Acurx Pharmaceuticals, Inc.
Headquarters259 LIBERTY AVENUE, STATEN ISLAND, NY, 10305
Founded2017
BIOPHARMAWATCH ELITE PLUS
Trade the next ACXP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime